The automation of the implant procedure is the part of the Neuralink update that actually matters. Forty-five patients across three continents is still pilot scale. The robot doing the surgery is what makes this a product at all.

For forty years cortical implant economics ran inside a constraint nobody outside the operating room could see. Each device required a neurosurgeon willing and able to place electrode arrays into living cortical tissue at sub-millimeter precision. The Utah Array hit that wall and stayed stuck in research for two decades. Neuralink's polymer threads are thinner than any human hand can guide. The robot is the precondition of the device existing at scale.

The Breakthrough Designation FDA issued for speech restoration starts pricing in a path where the Class III device is also a high-volume product, an arithmetic the regulator has not had to perform for any cortical implant in history.